Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yangqiu Li

Showing results (31-40 of 291) with videos related to

Pageof 30
Sort By:
European Journal of Pharmacology|June 5, 2020
Regulation of PD-1 in T cells for cancer immunotherapyXibao Yu, Rili Gao, Yangqiu Li, et al.
Cell Biology and Toxicology|October 23, 2016
Notch pathway plays a novel and critical role in regulating responses of T and antigen-presenting cells in aGVHDXiaodan Luo, Lihua Xu, Yangqiu Li, et al.
Oncology Letters|August 20, 2019
Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulationChanli Zheng, Yu Xiao, Yangqiu Li, et al.
Experimental Hematology & Oncology|June 20, 2022
TCR engineered T cells for solid tumor immunotherapyYikai Zhang, Zhipeng Liu, Wei Wei, et al.
Blood Science (Baltimore, Md.)|December 15, 2022
Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosisDingrui Nie, Cunte Chen, Yangqiu Li, et al.
European Journal of Pharmacology|March 15, 2022
The role of NFAT in the pathogenesis and targeted therapy of hematological malignanciesRili Gao, Yikai Zhang, Chengwu Zeng, et al.
Hematology (Amsterdam, Netherlands)|February 17, 2021
High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemiaCunte Chen, Chi Leong Chio, Hui Zeng, et al.
European Journal of Pharmacology|April 17, 2026
The Precision Revolution: Machine Learning and the Future of Personalized Therapy in Hematologic MalignanciesLing Xu, Yangqiu Li, Michał Marczyk, et al.
Journal of Hematology & Oncology|September 29, 2023
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapyLetong Cai, Yuchen Li, Jiaxiong Tan, et al.
Cell Biology International|July 22, 2014
Gene expression profile analysis of SUDHL6 cells with siRNA-mediated BCL11A downregulationHong Wu, Yangjun Gao, Li Ding, et al.
Pageof 30

Showing results (31-40 of 291) with videos related to

Sort By:
Pageof 30
European Journal of Pharmacology|June 5, 2020
Regulation of PD-1 in T cells for cancer immunotherapyXibao Yu, Rili Gao, Yangqiu Li, et al.
Cell Biology and Toxicology|October 23, 2016
Notch pathway plays a novel and critical role in regulating responses of T and antigen-presenting cells in aGVHDXiaodan Luo, Lihua Xu, Yangqiu Li, et al.
Oncology Letters|August 20, 2019
Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulationChanli Zheng, Yu Xiao, Yangqiu Li, et al.
Experimental Hematology & Oncology|June 20, 2022
TCR engineered T cells for solid tumor immunotherapyYikai Zhang, Zhipeng Liu, Wei Wei, et al.
Blood Science (Baltimore, Md.)|December 15, 2022
Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosisDingrui Nie, Cunte Chen, Yangqiu Li, et al.
European Journal of Pharmacology|March 15, 2022
The role of NFAT in the pathogenesis and targeted therapy of hematological malignanciesRili Gao, Yikai Zhang, Chengwu Zeng, et al.
Hematology (Amsterdam, Netherlands)|February 17, 2021
High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemiaCunte Chen, Chi Leong Chio, Hui Zeng, et al.
European Journal of Pharmacology|April 17, 2026
The Precision Revolution: Machine Learning and the Future of Personalized Therapy in Hematologic MalignanciesLing Xu, Yangqiu Li, Michał Marczyk, et al.
Journal of Hematology & Oncology|September 29, 2023
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapyLetong Cai, Yuchen Li, Jiaxiong Tan, et al.
Cell Biology International|July 22, 2014
Gene expression profile analysis of SUDHL6 cells with siRNA-mediated BCL11A downregulationHong Wu, Yangjun Gao, Li Ding, et al.
Pageof 30